Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California. Show more

4350 Executive Drive, San Diego, CA, 92121, United States

https://oncolyticsbiotech.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

90.0M

52 Wk Range

$0.33 - $1.51

Previous Close

$0.78

Open

$0.77

Volume

727,226

Day Range

$0.77 - $0.84

Enterprise Value

85.61M

Cash

5.202M

Avg Qtr Burn

-6.733M

Insider Ownership

2.78%

Institutional Own.

3.27%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Pelareorep + paclitaxel + avelumab (Bavencio®) Details Breast cancer	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep + Atezolizumab (Tecentriq) Details 2L Squamous Cell Carcinoma of Anal Canal (SCAC)	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep + gemcitabine, nab-paclitaxel, atezolizumab Details metastatic pancreatic ductal adenocarcinoma (mPDAC)	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep + Bevacizumab + FOLFIRI (Oncolytic Virus) Details KRAS-Mutant MSS Metastatic Colorectal Cancer (2L)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep + Retifanlimab Details Triple-negative breast cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep + modified FOLFIRINOX +/- atezolizumab Details Metastatic pancreatic cancer (mPDAC)	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep + Keytruda® Details Pancreatic cancer, Sarcoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep +/- Atezolizumab Details Cancer, Breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.